Plasma Fibroblast Growth Factor 23 Concentration Is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Prié, Dominique ^a   Forand, Anne ^b   Francoz, Claire ^c   Elie, Caroline ^a   Cohen, Isabelle ^b   Courbebaisse, Marie ^a   Eladari, Dominique ^a   Lebrec, Didier ^c   Durand, François ^c   Friedlander, Gerard ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DIETHYLNITROSAMINE; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; SODIUM; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; LIVER GRAFT; LIVER INJURY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; BLOOD; LIVER DISEASE; MIDDLE AGED; YOUNG ADULT;

MUS;

ADULT; AGED; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; WAITING LISTS; YOUNG ADULT;

EID: 84879335593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066182     Document Type: Article

References (56)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N, (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
2. Nagasaki T, Lieberman MA, (1991) Liver contains heparin-binding growth factors as the major growth factor for cultured fibroblasts. Hepatology 13: 6-14.
3. Mirams M, Robinson BG, Mason RS, Nelson AE, (2004) Bone as a source of FGF23: regulation by phosphate? Bone 35: 1192-1199.
4. Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M, et al. (2013) Fibroblast Growth Factor 23 and Klotho Are Present in the Growth Plate. Connective Tissue Research 54: 108-117.
5. Yu C, Wang F, Jin C, Huang X, Miller DL, et al. (2003) Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 163: 1653-1662.
6. Jin-no K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T, (1997) Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 32: 119-121.
7. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW, (2002) Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 160: 641-654.
8. Uematsu S, Higashi T, Nouso K, Kariyama K, Nakamura S, et al. (2005) Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20: 583-588.
9. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, et al. (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 53: 854-864.
10. Prie D, Urena Torres P, Friedlander G, (2009) Latest findings in phosphate homeostasis. Kidney Int 75: 882-889.
11. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, et al. (2005) Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549.
12. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505.
13. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, et al. (2003) Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 2206-2211.
14. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435.
15. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.
16. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, et al. (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23: 1509-1518.
17. Ferrari SL, Bonjour JP, Rizzoli R, (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524.
18. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT, (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89: 4489-4492.
19. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, et al. (2005) 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-1042.
20. Burnett SAM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, et al. (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196.
21. Antoniucci DM, Yamashita T, Portale AA, (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 3144-3149.
22. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, et al. (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215.
23. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB, (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279.
24. Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, et al. (2011) FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation 121: 4393-4408.
25. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796.
26. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592.
27. Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, et al. (2012) Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney International.
28. Gruson D, Lepoutre T, Ketelslegers J-M, Cumps J, Ahn SA, et al. (2012) C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 37: 258-262.
29. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, et al. (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152: 640-648.
30. Isakova T, Xie H, Yang W, Xie D, Anderson AH, et al. (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439.
31. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. (2011) FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. Journal of the American Society of Nephrology 22: 1913-1922.
32. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, et al. (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608.
33. Kamath PS, Kim WR, (2007) The model for end-stage liver disease (MELD). Hepatology 45: 797-805.
34. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, et al. (2006) Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130: 1652-1660.
35. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, et al. (2005) Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41: 32-39.
36. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, et al. (2004) Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 40: 802-810.
37. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, et al. (2005) Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 11: 336-343.
38. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464-470.
39. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
40. Cox DR, (1972) Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B (Methodological) 34: 187-220.
41. Kaplan EL, Meier P, (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association 53: 457-481.
42. FIne JP, Gray RJ, (1999) A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association 94: 496-509.
43. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23: 164-176.
44. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, et al. (2008) Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359: 1018-1026.
45. Gotthardt D, Weiss KH, Baumgartner M, Zahn A, Stremmel W, et al. (2009) Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol 9: 72.
46. Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL, (2005) Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 242: 244-251.
47. Londono MC, Cardenas A, Guevara M, Quinto L, de Las Heras D, et al. (2007) MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 56: 1283-1290.
48. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, et al. (2007) An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 13: 1174-1180.
49. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, et al. (2011) Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality. Journal of the American Society of Nephrology 22: 956-966.
50. Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, et al. (2011) Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. European Journal of Clinical Investigation: no-no.
51. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, et al. (2011) The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. European Heart Journal.
52. Gutierrez OM, Wolf M, Taylor EN (2011) Fibroblast Growth Factor 23, Cardiovascular Disease Risk Factors, and Phosphorus Intake in the Health Professionals Follow-up Study. Clin J Am Soc Nephrol.
53. Zittermann A, Schleithoff SS, Frisch S, Gotting C, Kuhn J, et al. (2009) Circulating calcitriol concentrations and total mortality. Clin Chem 55: 1163-1170.
54. Lang PO, Samaras N, Samaras D, Aspinall R (2012) How important is vitamin D in preventing infections? Osteoporos Int.
55. Consortium A, (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348.
56. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, et al. (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 3179-3182.